Patents Assigned to Tekmira Pharmaceuticals Corporation
-
Patent number: 9801874Abstract: Improved methods for efficiently constituting liposome encapsulated vincristine for intravenous injection (VSLI) with reduced risk of operational errors and contamination are disclosed.Type: GrantFiled: November 20, 2013Date of Patent: October 31, 2017Assignees: Spectrum Pharmaceuticals, Tekmira Pharmaceuticals CorporationInventors: William T. Monte, Christopher James Barbosa, Thomas Philip Weber
-
Publication number: 20160375137Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.Type: ApplicationFiled: October 22, 2013Publication date: December 29, 2016Applicant: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
-
SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS
Publication number: 20160367687Abstract: The invention relates to compositions and methods for site-specific delivery of nucleic acids by combining them with targeting ligands and endosomolytic components.Type: ApplicationFiled: April 19, 2016Publication date: December 22, 2016Applicant: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Muthusamy Jayaraman -
Publication number: 20160317676Abstract: A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.Type: ApplicationFiled: May 11, 2016Publication date: November 3, 2016Applicants: Tekmira Pharmaceuticals Corporation, The University of British Columbia, Acuitas Therapeutics Inc.Inventors: Michael J. Hope, Thomas D. Madden, Pieter R. Cullis, Martin Maier, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Akin Akinc, Muthiah Manoharan, Ismail Hafez
-
Publication number: 20160250354Abstract: A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unsaturation can include cycloalkyl groups, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups. The lipid particle is suitable for delivering an active agent.Type: ApplicationFiled: January 29, 2016Publication date: September 1, 2016Applicant: TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Muthiah Manoharan, Kallanthotthathil Rajeev, Muthusamy Jayaraman, Michael Jung
-
Publication number: 20160213785Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: ApplicationFiled: November 30, 2015Publication date: July 28, 2016Applicant: TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Jayaprakash K. Narayanannair, Muthusamy Jayaraman, Laxman Eltepu
-
Publication number: 20160199485Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40 K), optionally substituted mPEG (mw 120-40 K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: ApplicationFiled: October 15, 2015Publication date: July 14, 2016Applicant: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
Patent number: 9345780Abstract: The invention relates to compositions and methods for site-specific delivery of nucleic acids by combining them with targeting ligands and endosomolytic components.Type: GrantFiled: October 1, 2013Date of Patent: May 24, 2016Assignee: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Muthusamy Jayaraman -
Publication number: 20160095924Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: August 28, 2015Publication date: April 7, 2016Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
-
Publication number: 20160024498Abstract: This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.Type: ApplicationFiled: April 30, 2015Publication date: January 28, 2016Applicant: TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Akin Akinc, Martin A. Maier
-
Patent number: 9220683Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)).Type: GrantFiled: November 10, 2009Date of Patent: December 29, 2015Assignee: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Jayaprakash K. Narayanannair, Muthusamy Jayaraman, Laxmab Eltepu
-
Patent number: 9186325Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alky lhetro cycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: GrantFiled: November 10, 2009Date of Patent: November 17, 2015Assignee: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Publication number: 20150297519Abstract: The present invention provides a novel in vitro release assay for the accurate, reproducible quantitation of vincristine sulfate release from liposomes.Type: ApplicationFiled: December 4, 2013Publication date: October 22, 2015Applicant: TEKMIRA PHARMACEUTICALS CORPORATIONInventor: Thomas Philip WEBER
-
Publication number: 20150265708Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: ApplicationFiled: February 24, 2015Publication date: September 24, 2015Applicant: TEKMIRA PHARMACEUTICALS CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Narayanannair, Martin Maier, Laxman Eltepu
-
Patent number: 9139554Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: October 9, 2009Date of Patent: September 22, 2015Assignees: Tekmira Pharmaceuticals Corporation, The University of British ColumbiaInventors: Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
-
Patent number: 9051567Abstract: This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that increases LDL receptor levels.Type: GrantFiled: June 15, 2010Date of Patent: June 9, 2015Assignee: Tekmira Pharmaceuticals CorporationInventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Akin Akinc, Martin A. Maier
-
Patent number: 8999351Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: GrantFiled: November 10, 2009Date of Patent: April 7, 2015Assignee: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Narayanannair, Martin Maier, Laxman Eltepu
-
Patent number: 8883202Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).Type: GrantFiled: May 5, 2010Date of Patent: November 11, 2014Assignee: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Michael E. Jung
-
Patent number: 8802644Abstract: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.Type: GrantFiled: January 25, 2012Date of Patent: August 12, 2014Assignee: Tekmira Pharmaceuticals CorporationInventors: Jianxin Chen, Steven Ansell, Akin Akinc, Joseph Robert Dorkin, Xiaojun Qin, William Cantley, Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
-
Publication number: 20140179761Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.Type: ApplicationFiled: October 22, 2013Publication date: June 26, 2014Applicant: Tekmira Pharmaceuticals CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman